GeoVax Labs (GOVX) investor relations material

Executive summary

• Advanced GEO-MVA (mpox/smallpox vaccine) toward a pivotal immunobridging study under expedited EMA regulatory pathway, targeting Phase 3 initiation in late 2026 or Q4 2026.

• Gedeptin (oncology) completed Phase 1/2 and is advancing into combination and neoadjuvant strategies, with a Phase 2 trial planned for 2027.

• Strategic reprioritization in May 2026 shifted resources to GEO-MVA and Gedeptin, discontinuing COVID-19 vaccine development.

• Manufacturing platform development continues, emphasizing scalable, high-yield vaccine production.

Financial highlights

• No revenue reported in Q2 or H1 2026 due to BARDA contract termination; prior year Q2 revenue was $852,282 and H1 revenue was $2,489,145.

• Net loss for Q2 2026 was $4.43 million ($0.97/share), improved from $5.37 million ($8.74/share) in Q2 2025; H1 2026 net loss was $9.69 million ($2.94/share), improved from $10.73 million ($19.72/share) in H1 2025.

• Research and development expenses decreased 34.2% year-over-year for Q2 and 30.4% for H1, primarily due to discontinued BARDA contract and lower clinical trial costs.

• General and administrative expenses decreased 13.7% (Q2) and 16.4% (H1) year-over-year, with reductions in investor relations and stock-based compensation.

• Cash and cash equivalents were $3.14 million as of June 30, 2026, compared to $3.09 million at year-end 2025.

Outlook and guidance

• Existing cash is expected to fund operations into September 2026; substantial doubt remains about ability to continue as a going concern without additional capital.

• Plans to seek further funding through equity, debt, grants, or partnerships; failure to secure funding may require delaying or reducing development programs.

• Pivotal GEO-MVA immunobridging study planned for Q4 2026 initiation, aiming for regulatory approval and commercial readiness.